<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00162669</url>
  </required_header>
  <id_info>
    <org_study_id>IGR 1123</org_study_id>
    <secondary_id>HCC-Avastin</secondary_id>
    <nct_id>NCT00162669</nct_id>
  </id_info>
  <brief_title>Bevacizumab in Advanced Hepatocellular Carcinoma</brief_title>
  <official_title>Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <brief_summary>
    <textblock>
      Primary liver cancer (hepatocellular carcinoma) is the fifth most common malignant disorder,&#xD;
      with an increasing incidence in Europe and the USA as a result of the high prevalence of&#xD;
      hepatitis C. Most patients are not suitable for potentially curative treatment. There is no&#xD;
      standard palliative treatment for patients with advanced hepatocellular carcinoma (HCC), as&#xD;
      no drug has been demonstrated to be efficient in this disease in terms of survival. The use&#xD;
      of anti-vascular agents might be a promising approach in view of the highly vascular nature&#xD;
      of this tumor. The aim of this phase II trial is to evaluate the potential benefit of&#xD;
      bevacizumab in terms of disease control rate, progression-free and overall survival in adult&#xD;
      patients with advanced primary liver cancer. Bevacizumab is an angiogenesis inhibitor already&#xD;
      successfully used in patients with colorectal and renal cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2005</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The main response parameter will be the disease control rate, defined by the objective response and stable disease rate (Response Evaluation Criteria in Solid Tumors [RECIST criteria]) after two consecutive tumor evaluations during treatment.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, progression-free survival, toxicity (National Cancer Institute-Common Toxicity Criteria Version 3 [NCI-CTC V3])</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of vascular changes will be performed using Doppler ultrasound with injection of sonographic contrast agent</measure>
  </secondary_outcome>
  <enrollment>50</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven HCC or alpha-fetoprotein level &gt; 400 ng/ml&#xD;
             together with hypervascular tumor and cirrhosis documented by CT scan or MRI.&#xD;
&#xD;
          -  HCC not amenable to curative treatment (resection, transplantation, percutaneous&#xD;
             ablation)&#xD;
&#xD;
          -  Presence of at least one dimensionally measurable target lesion with largest diameter&#xD;
             &gt;= 2 cm.&#xD;
&#xD;
          -  No previous chemoembolization, no previous radiotherapy&#xD;
&#xD;
          -  Cancer of the Liver Italian Program (CLIP) score &lt; 4&#xD;
&#xD;
          -  World Health Organization (WHO) performance status of 2 or less&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months.&#xD;
&#xD;
          -  Age &gt;= 18 years.&#xD;
&#xD;
          -  Adequate hematologic functions (neutrophil count, at least 1500 per cubic millimeter;&#xD;
             platelet count, at least 75,000 per cubic millimetre; Hemoglobin, at least 8 g/dl)&#xD;
&#xD;
          -  Adequate liver function (bilirubin, not more than 2 times the upper limit of normal);&#xD;
             Adequate renal function (serum creatinine, less than 150 micromol per liter)&#xD;
&#xD;
          -  Adequate coagulation function&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated cirrhosis (Child-Pugh score &gt; 7)&#xD;
&#xD;
          -  CLIP score &gt; 4&#xD;
&#xD;
          -  Variceal bleeding during the previous 3 months&#xD;
&#xD;
          -  Thromboembolic event during the previous 6 months&#xD;
&#xD;
          -  Medical condition requiring full dose anticoagulation or anti-platelet drugs&#xD;
&#xD;
          -  Abnormal cardiac function with history of ischemic heart disease in the previous 6&#xD;
             months, uncontrolled hypertension, unstable angina, severe cardiac arrhythmia,&#xD;
&#xD;
          -  No brain metastasis, No bone metastasis only&#xD;
&#xD;
          -  Previous or current malignancies at other sites&#xD;
&#xD;
          -  No concomitant antitumor treatment including tamoxifen or somatostatin analogs&#xD;
&#xD;
          -  Unstable systemic diseases or active uncontrolled infections.&#xD;
&#xD;
          -  Patients (male and female) not using effective contraception if of reproductive&#xD;
             potential.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valérie BOIGE, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valerie Boige, MD</last_name>
    <phone>00 33 014-211-4308</phone>
    <email>boige@igr.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Pierre Pignon, MD, PhD</last_name>
    <phone>00 33 014-211-4565</phone>
    <email>jppignon@igr.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie BOIGE, Dr</last_name>
      <phone>00 33 014 211 43 08</phone>
      <email>boige@igr.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2005</study_first_posted>
  <last_update_submitted>September 7, 2006</last_update_submitted>
  <last_update_submitted_qc>September 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2006</last_update_posted>
  <keyword>Hepatocellular carcinoma, advanced, bevacizumab, phase II, VGEF, neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

